Vertex Pharmaceuticals Incorporated VRTX NASDAQ

Vertex Pharmaceuticals Incorporated (VRTX) has shown strong revenue growth over the past 3 years, expanding from $8.9B to $12.1B (average +10.6%/yr). Net income reached $4.0B, reflecting exceptional earnings expansion at +244.1%/yr on average. The net profit margin is 32.7%, which is exceptional. the company was profitable in 3 out of the last 4 years tracked. The gross margin is 85% (high), with a -2.9pp trend over the period. With a $113B market cap and MOAT composite score of 81/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (90/100, Pass) — proving strong growth momentum
• PAST (75/100, Partial) — profitability has been inconsistent. Looking at the full 36-year history, the company was profitable in 10 of 36 years — a mixed long-term record
• INCOME (100/100, Pass) — proves strong profitability and pricing power
• MOAT (81/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 84/100 with 5/7 criteria passed.